Effect of nesiritide (B-type natriuretic peptide) and dobutamine on ventricular arrhythmias in the treatment of patients with acutely decompensated congestive heart failure: The PRECEDENT study
Andrew J. Burger(Beth Israel Deaconess Medical Center), Uri Elkayam(University of Southern California), Thierry H. LeJemtel(University of Maryland, Baltimore), George W. Dennish, Guillermo Torre‐Amione(Cornell University), Jay Dinerman(Harvard University Press), Michael Koren(Harvard University Press), Mei Cheng(Pharmacyclics (United States)), Marc A. Silver(Harvard University Press), Darlene P. Horton(Napo Pharmaceuticals (United States)), Jalal K. Ghali(Launchpad Central (United States))
Cited by 323
Related Papers
Characteristics and outcomes of patients hospitalized for heart failure in the United States: Rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE)
|American Heart Journal|2005|2.1k
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.6k
Intravenous Nesiritide, a Natriuretic Peptide, in the Treatment of Decompensated Congestive Heart Failure
|New England Journal of Medicine|2000|908
Sustained hemodynamic effects of an infusion of nesiritide (human b-type natriuretic peptide) in heart failure
|Journal of the American College of Cardiology|1999|323